-
NICE rejects Ocrevus for PPMS, citing cost concerns
- July 3, 2018
- Posted by: PharmaScroll
- Category:
No Comments -
α-Linolenic acid can reduce disease activity in multiple sclerosis patients, study finds
- June 29, 2018
- Posted by: PharmaScroll
- Category:
-
New mobile app can help MS patients manage their disease better
- June 28, 2018
- Posted by: PharmaScroll
- Category:
-
Oromucosal Cannabinoid Spray reduces pain in MS patients, study finds
- June 26, 2018
- Posted by: PharmaScroll
- Category:
-
NICE approves Ocrevus in RRMS but with certain conditions
- June 23, 2018
- Posted by: PharmaScroll
- Category:
-
Phase 1 trial announced for a potential MS drug RTA 1701
- June 22, 2018
- Posted by: PharmaScroll
- Category:
-
Latest data on Ublituximab Ph 2 study in MS patients announced at EAN
- June 20, 2018
- Posted by: PharmaScroll
- Category:
-
Additional Cladribine data reinforces efficacy in RMS patients
- June 20, 2018
- Posted by: PharmaScroll
- Category:
-
Roche announces long term disability data for Ocrevus in PPMS patients
- June 18, 2018
- Posted by: PharmaScroll
- Category:
-
Biogen launches Aby App for Multiple Sclerosis patients
- June 14, 2018
- Posted by: PharmaScroll
- Category: